La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cibus Gestione

Gestione criteri di controllo 1/4

Cibus' Il CEO è Rory Riggs, nominato in Jan2001, e ha un mandato di 23.58 anni. la retribuzione annua totale è $ 292.31K, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 14.22% delle azioni della società, per un valore di $ 28.10M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 1.2 anni.

Informazioni chiave

Rory Riggs

Amministratore delegato

US$292.3k

Compenso totale

Percentuale dello stipendio del CEO	100.0%
Mandato del CEO	23.6yrs
Proprietà del CEO	14.2%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	1.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Aug 17

Analysts Just Shaved Their Calyxt, Inc. (NASDAQ:CLXT) Forecasts Dramatically

May 11

Calyxt, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rory Riggs rispetto agli utili di Cibus?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$292m
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

Compensazione vs Mercato: La retribuzione totale di Rory ($USD 292.31K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Rory con le performance aziendali.

AMMINISTRATORE DELEGATO

Rory Riggs (71 yo)

23.6yrs

Mandato

US$292,314

Compensazione

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rory Riggs	Co-Founder	23.6yrs	US$292.31k	14.22% $ 28.0m
Peter Beetham	Co-Founder	1.2yrs	US$292.31k	0.33% $ 659.0k
Greg Gocal	Co-Founder	8.6yrs	US$266.01k	0.28% $ 547.6k
Wade King	Chief Financial Officer	1.3yrs	Nessun dato	0.19% $ 368.9k
Jason Stokes	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
Rosa Kim	Senior Vice President of Legal	no data	Nessun dato	Nessun dato
James Radtke	Senior Vice President of Product Development	no data	Nessun dato	Nessun dato
Tony Moran	Senior Vice President of International Development	no data	Nessun dato	Nessun dato
Norm Sissons	Senior Vice President of Seed & Traits	no data	Nessun dato	Nessun dato
Noel Sauer	Senior Vice President of Research	no data	Nessun dato	Nessun dato
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

64yo

Età media

Gestione esperta: Il team dirigenziale di CBUS non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rory Riggs	Co-Founder	1.2yrs	US$292.31k	14.22% $ 28.0m
Peter Beetham	Co-Founder	1.2yrs	US$292.31k	0.33% $ 659.0k
Gerhard Prante	Independent Vice Chairman	1.2yrs	Nessun dato	0.32% $ 624.2k
Mark Finn	Lead Independent Director	1.2yrs	Nessun dato	0.29% $ 567.1k
Keith Walker	Independent Director	1.2yrs	Nessun dato	0.37% $ 732.0k
Joseph Ecker	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jean-Pierre Lehmann	Independent Director	1.2yrs	Nessun dato	7.77% $ 15.3m
Jan Leach	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Stephen Howell	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Richard Meagher	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

1.2yrs

Durata media

78yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CBUS non è considerato esperto (durata media del mandato 1.2 anni), il che suggerisce un nuovo consiglio.

Cibus Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

High number of new directors

Recent updates

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

Calyxt, Inc., Annual General Meeting, Jun 01, 2022

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Calyxt, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target increased to US$8.67

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Chief Financial Officer recently bought US$64k worth of stock